Nex Immune, Inc. NEXI
We take great care to ensure that the data presented and summarized in this overview for NexImmune, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in NEXI
Top Purchases
Top Sells
About NEXI
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Insider Transactions at NEXI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 11
2024
|
Kristi Jones President and CEO |
BUY
Open market or private purchase
|
Direct |
1
+50.0%
|
$0
$0.01 P/Share
|
|
Nov 22
2023
|
Alan S. Roemer Director |
SELL
Open market or private sale
|
Direct |
3,992
-100.0%
|
$3,992
$1.94 P/Share
|
|
Nov 21
2023
|
Alan S. Roemer Director |
SELL
Open market or private sale
|
Direct |
3,833
-48.98%
|
$7,666
$2.16 P/Share
|
|
Mar 30
2023
|
Sol J Barer |
BUY
Open market or private purchase
|
Direct |
400,000
+15.28%
|
$0
$0.41 P/Share
|
|
Nov 26
2022
|
Kristi Jones President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
296,700
+44.52%
|
-
|
|
Nov 22
2022
|
Mathias Oelke Chief Science Officer |
BUY
Grant, award, or other acquisition
|
Direct |
126,100
+48.48%
|
-
|
|
Nov 22
2022
|
John Trainer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,200
+40.11%
|
-
|
|
Nov 17
2022
|
Sol J Barer |
BUY
Open market or private purchase
|
Direct |
75,000
+3.96%
|
$0
$0.48 P/Share
|
|
Nov 16
2022
|
Sol J Barer |
BUY
Open market or private purchase
|
Direct |
125,000
+6.69%
|
$0
$0.48 P/Share
|
|
Jun 07
2022
|
Grant Verstandig |
BUY
Open market or private purchase
|
Direct |
26,876
+2.37%
|
$53,752
$2.28 P/Share
|
|
Jun 06
2022
|
Grant Verstandig |
BUY
Open market or private purchase
|
Direct |
25,000
+2.27%
|
$50,000
$2.14 P/Share
|
|
Jun 03
2022
|
Grant Verstandig |
BUY
Open market or private purchase
|
Direct |
15,000
+1.4%
|
$30,000
$2.22 P/Share
|
|
Jun 02
2022
|
Sol J Barer |
BUY
Open market or private purchase
|
Direct |
20,720
+1.26%
|
$41,440
$2.22 P/Share
|
|
Jun 02
2022
|
Grant Verstandig |
BUY
Open market or private purchase
|
Direct |
47,900
+4.41%
|
$95,800
$2.23 P/Share
|
|
Jun 01
2022
|
Sol J Barer |
BUY
Open market or private purchase
|
Direct |
40,000
+2.44%
|
$80,000
$2.35 P/Share
|
|
Jun 01
2022
|
Grant Verstandig |
BUY
Open market or private purchase
|
Direct |
40,200
+3.9%
|
$80,400
$2.38 P/Share
|
|
May 31
2022
|
Sol J Barer |
BUY
Open market or private purchase
|
Direct |
39,280
+2.46%
|
$78,560
$2.19 P/Share
|
|
May 31
2022
|
Grant Verstandig |
BUY
Open market or private purchase
|
Direct |
45,024
+4.52%
|
$90,048
$2.11 P/Share
|
|
Mar 29
2022
|
Kristi Jones President and CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+12.04%
|
$30,000
$3.74 P/Share
|
|
Mar 28
2022
|
Grant Verstandig |
BUY
Open market or private purchase
|
Direct |
18,983
+2.05%
|
$56,949
$3.76 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 1 shares |
|---|